Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash from Operations (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Cash from Operations for 14 consecutive years, with 11828000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 54.17% year-over-year to 11828000.0, compared with a TTM value of 75369000.0 through Dec 2025, up 40.88%, and an annual FY2025 reading of 75369000.0, up 40.88% over the prior year.
  • Cash from Operations was 11828000.0 for Q4 2025 at Karyopharm Therapeutics, down from 5860000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 25475000.0 in Q4 2021 and bottomed at 59197000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 27612400.0, with a median of 26326500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations surged 183.16% in 2021, then tumbled 205.37% in 2022.
  • Year by year, Cash from Operations stood at 25475000.0 in 2021, then crashed by 205.37% to 26843000.0 in 2022, then surged by 30.76% to 18585000.0 in 2023, then plummeted by 38.88% to 25810000.0 in 2024, then surged by 54.17% to 11828000.0 in 2025.
  • Business Quant data shows Cash from Operations for KPTI at 11828000.0 in Q4 2025, 5860000.0 in Q3 2025, and 18697000.0 in Q2 2025.